Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and has a median survival after diagnosis of 2–5 years. Pirfenidone is the first approved antifibrotic drug for the treatment of IPF. Here we report the functional progress, side effects and survival...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ther Adv Respir Dis
Autori principali: Vietri, Lucia, Cameli, Paolo, Perruzza, Marco, Cekorja, Behar, Bergantini, Laura, d’Alessandro, Miriana, Refini, Rosa Metella, Pieroni, Maria, Fossi, Antonella, Bennett, David, Spalletti, Marco, Mazzei, Maria Antonietta, Sestini, Piersante, Rottoli, Paola, Bargagli, Elena
Natura: Artigo
Lingua:Inglês
Pubblicazione: SAGE Publications 2020
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7029533/
https://ncbi.nlm.nih.gov/pubmed/32066332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466620906326
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi